Literature DB >> 1373973

Bone marrow-derived stromal cells prevent apoptotic cell death in B-lineage acute lymphoblastic leukemia.

A Manabe1, E Coustan-Smith, F G Behm, S C Raimondi, D Campana.   

Abstract

Establishing requirements for the survival of human immature B cells in vitro has proved elusive. In this article, we report prolonged survival of B-lineage leukemic cells on 'feeder layers' of bone marrow (BM)-derived stromal cells in a serum-free environment. In 15 of 18 cases of B-lineage acute lymphoblastic leukemia (ALL), there was a greater than 50% decrease in the number of viable cells after 72 hours of culture in medium alone. Cell loss was preceded by molecular and cellular changes characteristic of programmed cell death, or apoptosis, and was not suppressed by adding interleukin-7 to the tissue culture medium. By contrast, the use of allogeneic BM stromal cells as feeder layers prevented apoptosis in 10 of 12 cases of ALL, leading to extended survival of the blast cells. This method was not successful when the allogeneic marrow cells were replaced with established cell lines. In six of eight cases in which the numbers of intact CD19+ lymphoblasts were counted by flow cytometry after 7 days of culture, the proportion of such cells recovered in the presence of BM stromal cells was 68.8% to 124.7% (median, 95.3%) of that originally seeded, as opposed to the 0.3% to 15.9% fraction (median, 0.7%) obtained in the absence of stromal cells. Survival requirements of the B-lineage lymphoblasts appeared to be heterogeneous, as cells from 3 of the 18 cases studied showed no signs of apoptosis in serum-free tissue culture medium that lacked BM stromal cells. The only cells not giving rise to viable cultures were from two hyperdiploid (greater than 50 chromosomes) cases with identical karyotypes. The serum-free assay described here can be used to compare the survival requirements of normal and leukemic B-cell progenitors as well as to identify the molecules involved in the interaction between BM stroma and immature B cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1373973

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  64 in total

Review 1.  The Wnt signaling pathway in cancer.

Authors:  Yann Duchartre; Yong-Mi Kim; Michael Kahn
Journal:  Crit Rev Oncol Hematol       Date:  2015-12-24       Impact factor: 6.312

Review 2.  A primitive cell origin for B-cell precursor ALL?

Authors:  C V Cox; A Blair
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

3.  A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).

Authors:  Todd M Cooper; Edward Allan Racela Sison; Sharyn D Baker; Lie Li; Amina Ahmed; Tanya Trippett; Lia Gore; Margaret E Macy; Aru Narendran; Keith August; Michael J Absalon; Jessica Boklan; Jessica Pollard; Daniel Magoon; Patrick A Brown
Journal:  Pediatr Blood Cancer       Date:  2017-04-14       Impact factor: 3.167

4.  Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.

Authors:  Christian Flotho; Elaine Coustan-Smith; Deqing Pei; Shotaro Iwamoto; Guangchun Song; Cheng Cheng; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

5.  Cloning of a novel membrane-linked metalloproteinase from human myeloma cells.

Authors:  N McKie; D J Dallas; T Edwards; J F Apperley; R G Russell; P I Croucher
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

6.  Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy.

Authors:  Yao-Te Hsieh; Eun Ji Gang; Huimin Geng; Eugene Park; Sandra Huantes; Doreen Chudziak; Katrin Dauber; Paul Schaefer; Carlton Scharman; Hiroyuki Shimada; Seyedmehdi Shojaee; Lars Klemm; Reshmi Parameswaran; Mignon Loh; Eun-Suk Kang; Hong Hoe Koo; Wolf-Karsten Hofmann; Jacob Andrade; Gay M Crooks; Cheryl L Willman; Markus Müschen; Thalia Papayannopoulou; Nora Heisterkamp; Halvard Bönig; Yong-Mi Kim
Journal:  Blood       Date:  2013-01-14       Impact factor: 22.113

7.  Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.

Authors:  Ashok Srinivasan; John C Panetta; Shane J Cross; Asha Pillai; Brandon M Triplett; David R Shook; Mari H Dallas; Christine Hartford; Anusha Sunkara; Guolian Kang; Jeffrey Jacobsen; John Choi; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2014-04-23       Impact factor: 5.742

Review 8.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

9.  Human Adipose Tissue Stem Cells Promote the Growth of Acute Lymphoblastic Leukemia Cells in NOD/SCID Mice.

Authors:  Myoung Woo Lee; Yoo Jin Park; Dae Seong Kim; Hyun Jin Park; Hye Lim Jung; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Keon Hee Yoo
Journal:  Stem Cell Rev Rep       Date:  2018-06       Impact factor: 5.739

10.  Wnt pathway contributes to the protection by bone marrow stromal cells of acute lymphoblastic leukemia cells and is a potential therapeutic target.

Authors:  Yang Yang; Saradhi Mallampati; Baohua Sun; Jing Zhang; Sang-Bae Kim; Ju-Seog Lee; Yun Gong; Zhen Cai; Xiaoping Sun
Journal:  Cancer Lett       Date:  2013-01-16       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.